


EHP-101

Chemical Properties

CAS No. : 1818428-24-8
 Formula: C₂₈H₃₅NO₃
 Molecular Weight: 433.58
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	EHP-101 (VCE-004.8) is a specific dual agonist of PPAR γ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity.
Targets(IC50)	Cannabinoid Receptor, HIF/HIF Prolyl-Hydroxylase, PPAR
In vivo	In HFD mice, VCE-004.8 (injection; 207mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) [1].

Solubility Information

Solubility	DMSO: 49 mg/mL (113.01 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.61 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.3064 mL	11.5319 mL	23.0638 mL
5 mM	0.4613 mL	2.3064 mL	4.6128 mL
10 mM	0.2306 mL	1.1532 mL	2.3064 mL
50 mM	0.0461 mL	0.2306 mL	0.4613 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Navarrete C, et al. Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy. *J Neuroinflammation*. 2018 Mar 1;15(1):64.

Palomares B, et al. VCE-004.8, A Multitarget Cannabinoquinone, Attenuates Adipogenesis and Prevents Diet-Induced Obesity. *Sci Rep*. 2018 Oct 31;8(1):16092.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481